SeylanMED

About:

SeylanMED is a biotech company that develops a targeted therapy for Seborrheic Keratosis.

Description:

SeylanMED is a biotech company that develops a targeted therapy for Seborrheic Keratosis. SeylanMED is committed to the development of a topical Akt inhibitor as a first in class treatment for Seborrheic Keratosis (SK). Our lead drug candidate, SM-020, is the first molecularly-targeted approach for the treatment of SK. SeylanMED is funded by angel investors including board-certified dermatologists.

Total Funding Amount:

$1.17M

Headquarters Location:

Berkeley, California, United States

Founded Date:

2016-01-01

Contact Email:

mark(AT)desouzatech.com

Founders:

Anna Mandinova, Mark De Souza, Victor Neel

Number of Employees:

1-10

Last Funding Date:

2019-07-24

IPO Status:

Private

Industries: